Making Dollars And Sense Out Of Copay Assistance
The number of prescriptions associated with the use of copay assistance is expected to grow by 15% per year over the next decade, but there is little agreement between pharmaceutical manufacturers and payors about the benefits and drawbacks of copay-assistance programs. Analyzing the copay assistance on a case-by-case-basis will help pharma and payors find common ground by revealing the actual impact and costs associated with each program.
You may also be interested in...
Will FDA-cleared prescription digital therapeutics be able to follow wellness, chronic disease and sleep disorder apps onto the formularies of major payers? For digital therapeutics companies investing in randomized controlled clinical trials, GMP manufacturing and FDA submissions for products, the current absence of public health insurance coverage is frustrating.
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.